Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Current trends on cannabidiol delivery systems: where are we and where are we going?

Full text
Author(s):
de Medeiros Ramalho, Izola Morais [1] ; Pereira, Daniel Torres [1] ; Lima Galvao, Giovanna Brunelly [2] ; Freire, Danielle Teixeira [2] ; Amaral-Machado, Lucas [1, 2] ; Alencar, Everton do Nascimento [2, 3] ; Tabosa do Egito, Eryvaldo Socrates [1, 2, 3]
Total Authors: 7
Affiliation:
[1] Fed Univ Rio Grande Norte UFRN, Grad Program Hlth Sci Ppgcsa, Natal, RN - Brazil
[2] Fed Univ Rio Grande Norte UFRN, Dept Pharm, Natal, RN - Brazil
[3] Fed Univ Rio Grande Norte UFRN, Grad Program Pharmaceut Nanotechnol Ppgnanofarma, Natal, RN - Brazil
Total Affiliations: 3
Document type: Review article
Source: Expert Opinion on Drug Delivery; v. 18, n. 11 JUL 2021.
Web of Science Citations: 0
Abstract

Introduction Cannabidiol (CBD), a phytocannabinoid from Cannabis sativa, has several therapeutic properties. However, its high lipophilicity, metabolization, and instability impair its bioavailability and translational use in clinical settings. Several advanced drug delivery systems (ADDSs) have been evaluated as CBD carriers to overcome these drawbacks. These systems can improve the CBD dissolution profile, protect it against metabolization, and produce a site-specific release, increasing its bioavailability and making CBD administration clinically effective. Areas covered This review summarizes scientific reports on cannabidiol advanced delivery systems (CBD-ADSs) that have been (i) developed, and (ii) applied therapeutically; reports published in the main scientific databases until January 2020 were included. Studies without experimental data and/or published in languages other than English were excluded. Moreover, pharmaceutical technology tools in CBD therapeutic use have been discussed, emphasizing the clinical translation of CBD carrier use. Expert opinion Studies reporting CBD-ADS use for medicinal applications were reviewed and revealed multifaceted systems that can overcome the physicochemical drawbacks of CBD and improve its biological activities. Therefore, researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols. Although several criteria remain to be met, our findings emphasize the potential of CBD-ADSs for translational therapeutics, particularly for neurological-disorders. (AU)

FAPESP's process: 14/50891-1 - INCT 2014: Translational Medicine
Grantee:Jaime Eduardo Cecilio Hallak
Support Opportunities: Research Projects - Thematic Grants